Epigenetic therapy using the CRISPR-dCas9 method accurately targets and reactivates zygote arrest 1 (ZAR1), allowing it to regain its role as a tumor suppressor (Deutschmeyer and Richter, 2020). The gene discussed is ZAR1; the disease is neoplasm.